Atlas Trials

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

Clinical trial NCT03573817 · COMPLETED

Trial details

NCT number
NCT03573817
Sponsor
Mylan Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic Obstructive Pulmonary Disease (COPD)
Start date
2018-05-31
Primary completion
2018-09-25
Enrollment
122

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.